Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report

MET tyrosine kinase inhibitors, capmatinib and tepotinib, have been recently introduced for the treatment of advanced NSCLC with MET exon 14 skipping mutations. Although interstitial lung disease (ILD) induced by these drugs is reported, its optimal management and whether they can be rechallenged re...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashiguchi, Mizuha Haraguchi, Sato, Takashi, Yamamoto, Hiroki, Watanabe, Rinako, Kagyo, Junko, Domoto, Hideharu, Shiomi, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888201/
https://www.ncbi.nlm.nih.gov/pubmed/35252894
http://dx.doi.org/10.1016/j.jtocrr.2021.100271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888201/
https://www.ncbi.nlm.nih.gov/pubmed/35252894
http://dx.doi.org/10.1016/j.jtocrr.2021.100271

Ejemplares similares